Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Crosses Below Two Hundred Day Moving Average – Time to Sell?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) shares crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.35 and traded as low as $2.31. Oramed Pharmaceuticals shares last traded at $2.33, with a volume of 30,850 shares trading hands.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, February 19th.

Oramed Pharmaceuticals Stock Down 0.4 %

The business has a 50-day moving average price of $2.30 and a 200-day moving average price of $2.35. The firm has a market capitalization of $93.93 million, a P/E ratio of 21.18 and a beta of 1.61.

Institutional Investors Weigh In On Oramed Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of ORMP. Boothbay Fund Management LLC boosted its position in shares of Oramed Pharmaceuticals by 2.0% during the 4th quarter. Boothbay Fund Management LLC now owns 845,188 shares of the biotechnology company’s stock valued at $2,045,000 after acquiring an additional 16,857 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Oramed Pharmaceuticals by 143.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company’s stock valued at $288,000 after purchasing an additional 70,190 shares during the period. BML Capital Management LLC raised its holdings in shares of Oramed Pharmaceuticals by 20.9% in the 4th quarter. BML Capital Management LLC now owns 2,643,907 shares of the biotechnology company’s stock worth $6,398,000 after buying an additional 457,716 shares in the last quarter. World Equity Group Inc. bought a new position in shares of Oramed Pharmaceuticals during the 4th quarter worth approximately $48,000. Finally, Peapod Lane Capital LLC acquired a new stake in Oramed Pharmaceuticals in the 4th quarter valued at $550,000. Institutional investors own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.